Elrggal Mahmoud E, Haseeb Abdul, AlGethamy Manal, Ahsan Umar, Saleem Zikria, Althaqafi Areej Sultan, Alshuail Sattam Saad, Alsiddiqi Zohair Ahmad, Iqbal Muhammad Shahid, Alzahrani Albaraa Faraj, AlQarni Abdullmoin, Radwan Rozan Mohammad, Qul Ameer Khalid Saab, Mahrous Ahmad Jamal, Alsharif Jumana Majdi, Alqurashi Mayyasah Khalid, Faidah Hani Saleh, Aldurdunji Mohammed
Department of Clinical Pharmacy, College of Pharmacy, Umm AL-Qura University, Makkah, Saudi Arabia.
Department of Infection Prevention and Control Program, Alnoor Specialist Hospital Makkah, Makkah, Saudi Arabia.
Front Pharmacol. 2023 Mar 24;14:965284. doi: 10.3389/fphar.2023.965284. eCollection 2023.
Dose optimization of vancomycin plays a substantial role in drug pharmacokinetics because of the increased incidence of obesity worldwide. This systematic review was aimed to highlight the current dosing strategy of vancomycin among obese patients. This systematic review was in concordance with Preferred Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The literature search was carried out on various databases such as Scopus, PubMed/MEDLINE, ScienceDirect and EMBASE using Keywords and MeSH terms related to vancomycin dosing among obese patients. Google Scholar was also searched for additional articles. The English language articles published after January, 2000 were included in this study. The quality of the study was assessed using different assessment tools for cohort, and case reports. A total of 1,029 records were identified. After screening, 18 studies were included for the final review. Of total, twelve studies are retrospective and remaining six are case-control studies. A total of eight studies were conducted in pediatrics while remaining studies were conducted in adult population. Most of the studies reported the dosing interval every 6-8 h. Differences in target trough concentration exist with respect to target ranges. The administration of loading dose (20-25 mg/kg) followed by maintenance dose (15-25 mg/kg) of vancomycin is recommended in adult patients to target therapeutic outcomes. Moreover, a dose of 40-60 mg/kg/day appears appropriate for pediatric patients. The initial dosing of vancomycin based on TBW could be better predictor of vancomycin trough concentration. However, the clinical significance is uncertain. Therefore, more studies are needed to evaluate the dosing strategy of vancomycin in overweight or obese patients.
由于全球肥胖发生率的增加,万古霉素的剂量优化在药物药代动力学中起着重要作用。本系统评价旨在强调肥胖患者中万古霉素的当前给药策略。本系统评价符合系统评价和Meta分析的首选项目(PRISMA)指南。使用与肥胖患者万古霉素给药相关的关键词和医学主题词(MeSH),在Scopus、PubMed/MEDLINE、ScienceDirect和EMBASE等各种数据库中进行文献检索。还在谷歌学术上搜索了其他文章。本研究纳入了2000年1月以后发表的英文文章。使用不同的队列和病例报告评估工具对研究质量进行评估。共识别出1029条记录。筛选后,纳入18项研究进行最终审查。其中,12项研究为回顾性研究,其余6项为病例对照研究。共有8项研究在儿科进行,其余研究在成人中进行。大多数研究报告给药间隔为每6 - 8小时一次。关于目标范围,目标谷浓度存在差异。建议成年患者给予万古霉素负荷剂量(20 - 25mg/kg),随后给予维持剂量(15 - 25mg/kg)以达到治疗效果。此外,40 - 60mg/kg/天的剂量对儿科患者似乎是合适的。基于总体重(TBW)的万古霉素初始剂量可能是万古霉素谷浓度的更好预测指标。然而,其临床意义尚不确定。因此,需要更多研究来评估超重或肥胖患者中万古霉素的给药策略。